TY - JOUR
T1 - Bifunctional Antibody
T2 - A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma
AU - Stickney, Dwight R.
AU - Anderson, Leslie D.
AU - Slater, James B.
AU - Ahlem, Clarence N.
AU - Kirk, Gerald A.
AU - Schweighardt, Sally A.
AU - Frincke, James M.
N1 - In clinical studies we have evaluated a unique monoclonal antibody-based drug delivery system, a bifunctional antibody designed to deliver imaging or therapeutic agents, such as radioisotopes, drugs, or biologics, to tumor cells, while minimizing the dose to normal tissue. The bifunctional antibody, ...
PY - 1991/12
Y1 - 1991/12
N2 - In clinical studies we have evaluated a unique monoclonal antibodybased drug delivery system, a bifunctional antibody designed to deliver imaging or therapeutic agents, such as radioisotopes, drugs, or biologies, to tumor cells, while minimizing the dose to normal tissue. The bifunc tional antibody, with one specificity to a tumor-associated antigen (carcinoembryonic antigen) and another specificity to a hapten, is injected and allowed to localize at a tumor site for 4 days. A hapten, tagged with a radioisotope, is subsequently injected for delivery to and capture by the prelocalized antibody at the tumor site. In studies reported here, the sulfhydryl groups of Fab' fragments of ZCE-025 and CHA-255 were linked with bis-maleimidomethyl ether to form an Hab'): bifunctional antibody coupled by a stable thioether linkage. EOTUBE, a hydroxyethylthiourido derivative of benzyl EDTA, was used as the hapten carrier of '“In. Fourteen patients 62-82 years old with recurrent or metastatic adenocarcinoma of the colon were studied. Twenty of 21 known lesions were imaged, and eight of nine new lesions were confirmed. With this fundamentally new approach to drug delivery, clearance from normal tissue is rapid, and high tumornormal tissue ratios are expeditiously achieved.
AB - In clinical studies we have evaluated a unique monoclonal antibodybased drug delivery system, a bifunctional antibody designed to deliver imaging or therapeutic agents, such as radioisotopes, drugs, or biologies, to tumor cells, while minimizing the dose to normal tissue. The bifunc tional antibody, with one specificity to a tumor-associated antigen (carcinoembryonic antigen) and another specificity to a hapten, is injected and allowed to localize at a tumor site for 4 days. A hapten, tagged with a radioisotope, is subsequently injected for delivery to and capture by the prelocalized antibody at the tumor site. In studies reported here, the sulfhydryl groups of Fab' fragments of ZCE-025 and CHA-255 were linked with bis-maleimidomethyl ether to form an Hab'): bifunctional antibody coupled by a stable thioether linkage. EOTUBE, a hydroxyethylthiourido derivative of benzyl EDTA, was used as the hapten carrier of '“In. Fourteen patients 62-82 years old with recurrent or metastatic adenocarcinoma of the colon were studied. Twenty of 21 known lesions were imaged, and eight of nine new lesions were confirmed. With this fundamentally new approach to drug delivery, clearance from normal tissue is rapid, and high tumornormal tissue ratios are expeditiously achieved.
UR - http://www.scopus.com/inward/record.url?scp=0026333403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026333403&partnerID=8YFLogxK
M3 - Article
C2 - 1742739
SN - 0008-5472
VL - 51
SP - 6650
EP - 6655
JO - Cancer Research
JF - Cancer Research
IS - 24
ER -